Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Commentary|Articles|March 6, 2015
Augmenting Pre-Operative Risk of Recurrence Stratification in DTC
Author(s)R. Michael Tuttle, MD
R. Michael Tuttle, MD, discusses a study that looked at augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma.
Advertisement
Clinical Pearls
R. Michael Tuttle, MD, professor of medicine, Memorial Sloan Kettering Cancer Center, discusses a study that looked at augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma.
- This study set out to determine if data obtained during pre-operative nodule biopsy could be used to augment risk stratification.
- The ensemble classifier correctly identified 72.4% (21/29) of low risk tumors and 82.6% (43/52) of intermediate/high risk tumors.
- This represents another piece of information to help a physician decide on the proper approach to surgery.
Advertisement
Related to this article
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Advertisement
Advertisement
Trending on Targeted Onc
1
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
2
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
5